# Effects of BCG on Immune Response

> **NCT02085590** · PHASE2,PHASE3 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 20 (actual)

## Conditions studied

- Sepsis

## Interventions

- **BIOLOGICAL:** BCG vaccine
- **BIOLOGICAL:** Lipopolysaccharide (LPS) E. Coli 1 ng/kg intravenously

## Key facts

- **NCT ID:** NCT02085590
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2014-10
- **Final completion:** 2014-11
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2015-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02085590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02085590, "Effects of BCG on Immune Response". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02085590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*